Vyteris Holdings ( Nevada), Inc. (VYHN) announced that its board of directors has named Timothy J. McIntyre as Vyteris's new chief executive officer and member of the board.
McIntyre succeeds Vincent De Caprio, PhD, who is stepping down as chief executive officer and board member. Following his resignation, De Caprio will be a consultant and assist in the transition. In addition, Solomon Steiner, PhD, resigned from the board of directors for personal reasons. Steiner has been on the Vyteris board since December 2002 and will continue to advise the company as a member of the Vyteris Scientific Advisory Board.
McIntyre previously was partner, managing member of CMS-Health LLC, where he assisted in the development, financing and launch of new business models in the worldwide pharmaceutical services sector. Before that, he was a partner and managing member of Mediconsult/PharmaMarketing LLC and previous to that he was chief operating officer of Boron LePore Group Companies. McIntyre received his BA from the University of Notre Dame in South Bend, Indiana.
Vyteris Holdings ( Nevada), Inc. is a specialty pharmaceutical company organized to develop and manufacture pharmaceutical products based upon its drug delivery technology. The company's Actyve transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy.
This article was prepared by Pharma Investments, Ventures & Law Weekly editors from staff and other reports. Copyright 2006, Pharma Investments, Ventures & Law Weekly via LawRx.com.
# # #